Non-Alcoholic Fatty Pancreas Disease is Associated with SYNTAX Score in Acute Coronary Syndrome.
Acute coronary syndrome
Atherosclerosis
Ectopic adipose tissue
Non-alcoholic fatty pancreas disease
SYNTAX score
Journal
Acta Cardiologica Sinica
ISSN: 1011-6842
Titre abrégé: Acta Cardiol Sin
Pays: China (Republic : 1949- )
ID NLM: 101687085
Informations de publication
Date de publication:
Nov 2022
Nov 2022
Historique:
received:
08
01
2022
accepted:
24
04
2022
entrez:
28
11
2022
pubmed:
29
11
2022
medline:
29
11
2022
Statut:
ppublish
Résumé
Evidence that individuals with excess fat in the pancreas have an increased risk of cardiovascular disease has been growing recently. Risk evaluation in acute coronary syndrome (ACS) patients plays a crucial role for both prognosis prediction and decision-making. The main aim of this study was to investigate the relationship between non-alcoholic fatty pancreas disease (NAFPD) and the complexity and severity of coronary artery disease as assessed using the SYNTAX score (SXscore) in ACS patients. A total of 99 consecutive patients with a first-time diagnosis of ACS were recruited. NAFPD was evaluated using transabdominal ultrasonography (TUS). SXscore was calculated using the SXscore algorithm. The patients with NAFPD had a significantly higher SXscore than those without NAFPD (12.3 ± 6.4 and 8.2 ± 4.3, p < 0.001). Univariable analysis showed that hypertension (p = 0.033) and presence of NAFPD (p = 0.001) were associated with increased SXscore. Moreover, multivariable analysis showed that the presence of NAFPD (p = 0.002) was associated with increased SXscore. NAFPD is easily detected by TUS. The presence of NAFPD in ACS patients may be a warning signal of complexity and severity of coronary artery disease.
Sections du résumé
Background
UNASSIGNED
Evidence that individuals with excess fat in the pancreas have an increased risk of cardiovascular disease has been growing recently. Risk evaluation in acute coronary syndrome (ACS) patients plays a crucial role for both prognosis prediction and decision-making.
Aim
UNASSIGNED
The main aim of this study was to investigate the relationship between non-alcoholic fatty pancreas disease (NAFPD) and the complexity and severity of coronary artery disease as assessed using the SYNTAX score (SXscore) in ACS patients.
Methods
UNASSIGNED
A total of 99 consecutive patients with a first-time diagnosis of ACS were recruited. NAFPD was evaluated using transabdominal ultrasonography (TUS). SXscore was calculated using the SXscore algorithm.
Results
UNASSIGNED
The patients with NAFPD had a significantly higher SXscore than those without NAFPD (12.3 ± 6.4 and 8.2 ± 4.3, p < 0.001). Univariable analysis showed that hypertension (p = 0.033) and presence of NAFPD (p = 0.001) were associated with increased SXscore. Moreover, multivariable analysis showed that the presence of NAFPD (p = 0.002) was associated with increased SXscore.
Conclusions
UNASSIGNED
NAFPD is easily detected by TUS. The presence of NAFPD in ACS patients may be a warning signal of complexity and severity of coronary artery disease.
Identifiants
pubmed: 36440242
doi: 10.6515/ACS.202211_38(6).20220424A
pmc: PMC9692214
doi:
Types de publication
Journal Article
Langues
eng
Pagination
683-690Références
Nutr Clin Pract. 2019 Oct;34 Suppl 1:S49-S56
pubmed: 31535735
Acta Cardiol Sin. 2019 Mar;35(2):118-125
pubmed: 30930559
Diabetes. 2005 Dec;54(12):3541-6
pubmed: 16306373
Angiology. 2019 Jul;70(6):569-570
pubmed: 30270633
Eur Heart J. 2012 Oct;33(20):2569-619
pubmed: 22922416
Angiology. 2020 Jan;71(1):77-82
pubmed: 31018673
Eur Heart J. 2011 Dec;32(23):2999-3054
pubmed: 21873419
J Am Coll Cardiol. 2014 Apr 15;63(14):1345-54
pubmed: 24530666
Angiology. 2013 Nov;64(8):604-8
pubmed: 23439214
Postepy Kardiol Interwencyjnej. 2018;14(1):52-58
pubmed: 29743904
Eur Heart J. 2012 Jan;33(1):113-9
pubmed: 22028386
JAMA. 2004 Jun 9;291(22):2727-33
pubmed: 15187054
Angiology. 2021 Sep;72(8):754-761
pubmed: 33663258
Clin Res Cardiol. 2020 Sep;109(9):1125-1139
pubmed: 32006156
Cardiovasc Diabetol. 2013 May 20;12:77
pubmed: 23688357
EuroIntervention. 2009 May;5(1):50-6
pubmed: 19577983
Curr Vasc Pharmacol. 2016;14(5):432-441
pubmed: 27456108
Acta Cardiol Sin. 2019 Sep;35(5):459-467
pubmed: 31571794
J Clin Endocrinol Metab. 2005 Mar;90(3):1434-9
pubmed: 15598678
Eur J Gastroenterol Hepatol. 2018 Apr;30(4):411-417
pubmed: 29309395
Nat Rev Gastroenterol Hepatol. 2011 Mar;8(3):169-77
pubmed: 21304475
Acta Cardiol Sin. 2021 May;37(3):232-238
pubmed: 33976506
Indian Heart J. 2017 Nov - Dec;69(6):752-756
pubmed: 29174253
JAMA. 2000 Aug 16;284(7):835-42
pubmed: 10938172
Anatol J Cardiol. 2017 Jan;17(1):56-63
pubmed: 27564776
Cardiol J. 2012;19(3):295-300
pubmed: 22641549
Angiology. 2018 Feb;69(2):158-163
pubmed: 28592149
Acta Cardiol Sin. 2020 Jan;36(1):1-7
pubmed: 31903002
Clin Endocrinol (Oxf). 2015 Nov;83(5):656-62
pubmed: 26201937
Eur J Cardiothorac Surg. 2018 Nov 1;54(5):896-903
pubmed: 29868854
Diabetes Res Clin Pract. 2014 Dec;106(3):590-6
pubmed: 25444353
EuroIntervention. 2005 Aug;1(2):219-27
pubmed: 19758907
Obesity (Silver Spring). 2008 Mar;16(3):522-30
pubmed: 18239594
Vasc Health Risk Manag. 2019 May 01;15:89-100
pubmed: 31118651